louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06024252: Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
Official title: Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: HCC
Lead sponsor: Zhongda Hospital
Sponsor class: OTHER
First posted: 2023-09-06
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The target population for the planned retrospective analysis of this project is patients who have been diagnosed with unresectable HCC according to the guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 Edition) and treated with TACE combined with atezolizumab + bevacizumab.

Brief summary: This study will evaluate the efficacy and safety of TACE combined with atezolizumab + bevacizumab in the treatment of unresectable hepatocellular carcinoma, and the treatment patterns of the combination regimen

Detailed description: This study is a multi-center, retrospective and observational real-world study to explore the efficacy, safety and treatment pattern of TACE combined with Atezolizumab + Bevacizumab in unresectable hepatocellular carcinoma. The target population for the planned retrospective analysis of this project is patients who have been diagnosed with unresectable HCC according to the guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 Edition) and treated with TACE combined with atezolizumab + bevacizumab.

Eligibility criteria: Inclusion Criteria:

1. All patients were diagnosed with unresectable hepatocellular carcinoma according to the guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 Edition);
2. Patients ≥ 18 years old, male or female;
3. Child-Pugh Class A and B liver function;
4. ECOG-PS score of 0 \~ 2 points;
5. Received TACE in combination with atezolizumab + bevacizumab for at least one interval of no more than eight weeks.

Exclusion Criteria:

1. Other primary malignancies;
2. Incomplete data, such as no baseline image that can be assessed according to RECIST 1.1 or mRECIST, and survival outcome.

Primary outcomes:
measure: Overall survival
timeFrame: 1 year
Secondary outcomes:
measure: Progression-Free Survival
timeFrame: 1 year
measure: Objective response rate
timeFrame: 1 year
measure: One-year survival rate
timeFrame: 1 year
measure: Immune-TACE PFS
timeFrame: 1 year
measure: Disease control rate
timeFrame: 1 year
measure: Treatment pattern
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Zhongda Hospital
name: Gao-Jun Teng, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03819452: Impact of Vitamin D on Acute Ischemic Stroke Prognosis
Official title: Impact of Vitamin D on Acute Ischemic Stroke Prognosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ischemic Stroke
Keywords: vitamin D
Ischemic Stroke
Lead sponsor: Abha International Private Hospital
Sponsor class: OTHER
Collaborators: name: Mansoura University
First posted: 2019-01-28
Enrollment: 59
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients attending to hospital settings diagnosed with ischemic stroke are investigated to have low level of vitamin D

Brief summary: This is a registry for all patients admitted to hospital settings with Ischemic stroke in Mansoura University Hospital. The registry will capture patients' data, investigations and vitamin D level on admission. Follow-up is taking place using MODIFIED RANKIN SCALE


Eligibility criteria: Inclusion Criteria:

* Newly diagnosed ischemic stroke not older than 48 hours

Exclusion Criteria:

* Ischemic stroke due to accidents or any trauma

Primary outcomes:
measure: Correlation of Vitamin D level and the Incidence of Ischemic Stroke
timeFrame: On admission
Secondary outcomes:
measure: impact of vitamin D on ischemic stroke in relationship with gender
timeFrame: On admission
Other outcomes:
Locations:
city: Mansourah
country: Egypt
facility: Mansoura University
state: Dakahlia
city: Basel
country: Switzerland
facility: IQVIA
Study officials:
affiliation: Abha International Private Hospital
name: Mohamed FLeifel, MD PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04553952: The Distribution of Gingival Display and Possible Related Factors Resulting in Gummy Smile
Official title: Evaluating the Distribution of Gingival Display and Possible Related Factors Resulting in Gummy Smile
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gummy Smile
Lead sponsor: Baskent University
Sponsor class: OTHER
First posted: 2020-09-18
Enrollment: 501
Sex: ALL
Minimum age (years): 20
Maximum age (years): 61
Standard ages: ADULT
Accepts healthy volunteers: yes
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who applied to Baskent University Faculty of Dentistry for seeking dental treatment

Brief summary: This study primarily aimed to evaluate smile line distribution and prevalence of gummy smile in patients. The secondary purpose was to examine parameters that might be risk factors for gummy smile.

Detailed description: this study primarily aimed to evaluate smile line distribution and prevalence of gummy smile in patients. The secondary purpose was to examine parameters that might be risk factors for gummy smile.Age, gender, marital status, medical history, and medication status of the patients were recorded. All individuals were instructed to sit on a dental chair and the measurments were made by using a millimetric ruler.Next, the patients were grouped according to Liebart's classification by gingival display at maximum smile as follows: Class 1.Excessive gingival display (Gummy smile): ≥ 3mm gingival display Class 2.High smile line: 0-2 mm of gingival display Class 3. Average smile line: Dental papilla is visible. Class 4. Low smile line: Gingival margin, dental papilla is not visible at all. Presence of altered passive eruption, short lip and hypermobile upper lip were also evaluated.

Eligibility criteria: Inclusion Criteria:

* presence of teeth in upper jaw
* Age between 18-65 years

Exclusion Criteria:

* Patients who have received and/or are receiving orthodontic treatment and patients who received gummy smile treatment were excluded.

Primary outcomes:
measure: Measurement of gingival display
timeFrame: 1 minute
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Baskent University,Department of Dentistry
Study officials:
References:
Clinical trial NCT00092352: A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)
Official title: A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Osteoarthritis
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2004-09-27
Enrollment: 395
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of osteoarthritis of the knee.

Detailed description: The duration of treatment is 6 weeks.

Eligibility criteria: Inclusion Criteria:

* Osteoarthritis of the knee which requires treatment with medication for pain relief

Exclusion Criteria:

* Any known allergy to the study drug

Primary outcomes:
measure: Osteoarthritis (OA) of the knee as measured by Patient Global Assessment of Response to Therapy (PGART) and WOMAC VA 3.0 over 6 weeks of treatment.
Secondary outcomes:
measure: OA of the knee as measured by PGART over 6 wks of treatment.
measure: WOMAC Question #1 over 6 wks of treatment.
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Birbara C, Ruoff G, Sheldon E, Valenzuela C, Rodgers A, Petruschke RA, Chang DJ, Tershakovec AM. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Curr Med Res Opin. 2006 Jan;22(1):199-210. doi: 10.1185/030079906X80242.
Clinical trial NCT02727452: Immediate Bonding and Caesarean Section
Official title: Effects of Immediate Bonding (Skin-to-skin Contact) During Caesarean Section- Psychobiological and Somatic Outcomes of Mother and Child
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: C-Section
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
First posted: 2016-04-04
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The randomised study analyzes the effects of immediate bonding (skin-to-skin contact) on different psychobiological and somatic outcomes of mother and child. The investigators compare 3 bonding conditions. Cortisol and Oxytocin are also measured during the bonding process.


Eligibility criteria: Inclusion Criteria:

* Mothers with elective Caesarean Section and their partners

Exclusion Criteria:

* premature birth
* severe diseases
* drug abuse

Primary outcomes:
measure: Changes in Cortisol Level
timeFrame: 30 and 60 minutes after bonding
Secondary outcomes:
measure: Depression
timeFrame: 1-3 days and 6 weeks after childbirth
measure: Mother-child-bonding
timeFrame: 1-3 days and 6 weeks after childbirth
measure: Child's heart ratio
timeFrame: 30 and 60 minutes after birth
measure: Child's oxygen saturation
timeFrame: 30 and 60 minutes after birth
measure: Child's temperature
timeFrame: 30 and 60 minutes after birth
measure: Oxytocin
timeFrame: 30 and 60 minutes after birth
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: University Hospital Frankfurt-Dept.Obstetrics and Perinatal Medicine
state: Hessen
Study officials:
affiliation: University Hospital Frankfurt-Dept. Obstetrics and Perinatal Medicine
name: Frank Louwen, Prof.
role: STUDY_DIRECTOR
References:
Clinical trial NCT06917352: Clinical Validation of the Norbert Health Device for Pulse Rate Measurement at Vigilant Clinical Testing
Official title: Clinical Validation of the Norbert Health Device for Pulse Rate Measurement
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Healthy
Lead sponsor: Norbert Health
Sponsor class: INDUSTRY
Collaborators: name: Vigilant Clinical Testing
First posted: 2025-04-08
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy subjects 18 years of age or older with the ability to consent to study and follow instructions needed for data collection. Data will be collected on enrolled patients including but not limited to diabetes, hypertension, cardiac conditions, circulation problems, medications, and other health issues that would affect blood circulation to skin. Subject enrollment for these comorbidities and others will be based on incidental enrollment from the pool of available subjects per site.

Brief summary: The study will evaluate the measuring pulse rate (PR) using the Norbert Device (ND) as compared to a reference heart rate measured using an electrocardiogram (ECG).

Detailed description: The study design is to validate the pulse rate accuracy. The study is a non-randomized, non-blinded single arm design to evaluate the clinical accuracy of the ND's pulse rate measurement compared to a reference heart rate manually measured by observing R-peaks in a standard concurrently recorded ECG from an FDA 510(k)-cleared reference clinical ECG (RCECG). The sponsor will ensure that the study staff enrolls a range of subjects.

Eligibility criteria: Inclusion Criteria:

* Inclusion Criteria:
* Subjects must be 18 years or older
* Ability to comprehend written consent and provide informed consent
* Ability to commit to and complete study related paperwork and activities (i.e. subject forms, have de-identified pictures taken, comply with periods of no movement, etc.)

Exclusion Criteria:

* Pregnant women
* Diagnosis of essential tremor or any medical condition causing tremors of the head or hands
* Facial tattoos, scars, large moles, beards/hair growth, birthmarks, vitiligo, skin conditions, facial discoloration, or heavy makeup within the areas of interest
* Inability for subject to avoid extreme movement during measurement reading windows
* Inability for subject to raise their hand during measurement reading windows
* No heart arrythmias
* Discretion of the Principal investigator or clinical study staff

Primary outcomes:
measure: Primary Objective
timeFrame: Approximately 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Irvine
country: United States
facility: Vigilant Clinical Testing
state: California
Study officials:
affiliation: Vigilant Clinical Testing
name: Tala Harake, Masters of Science
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01149252: Determination of the Efficacy and Safety of Psoralait Versus Placebo in the Treatment of Psoriasis
Official title: Determination of the Efficacy and Safety of Psoralait Versus Placebo in the Treatment of Psoriasis.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Psoriasis
Keywords: Psoriasis
Lead sponsor: Trima, Israel Pharmaceutical Products
Sponsor class: INDUSTRY
First posted: 2010-06-23
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and efficacy of a new product, Psoralait, as compared to a placebo in the treatment of psoriasis.


Eligibility criteria: Inclusion Criteria:

* Patients who have been clinically diagnosed as suffering from psoriasis and are or aren't scheduled for Narrow Band Ultraviolet B (UVB)phototherapy of affected areas,excluding face and genitalia.

Exclusion Criteria:

* Women who are pregnant, lactating, planning to become pregnant, or women of child-bearing potential who have not successfully been using the same medically acceptable contraceptive methods over the previous 3 months, e.g., oral contraceptive agents, intrauterine device (IUD) and barrier method plus spermicide.
* Use of topical anti psoriatic therapy (including topical retinoids, corticosteroids, or vitamin D analogs) on the areas to be treated within 2 weeks prior to the beginning of the study.
* Received systemic biologic therapy to treat psoriasis (for example: alefacept, etanercept, infliximab, adalimumab) within 12 weeks prior to the beginning of the study.
* Received systemic psoriasis therapy (for example: methotrexate, cyclosporine, systemic corticosteroids, retinoids such as acitretin) within 4 weeks prior to the beginning of the study.
* Received phototherapy (including laser), photo chemotherapy or climatotherapy within 4 weeks prior to the beginning of the study.
* Recent history (within past 12 months) of alcohol or substance abuse. Alcohol abuse will be defined as \>14 drinks per week (1 drink = 12 oz beer, 4 oz wine, or 1.5 oz distilled spirits).
* History of noncompliance to medical regimens or unwilling to comply with the study protocol.
* Participation in an investigational drug study within 30 days prior to the beginning of the study.
* Serious or unstable medical or psychological conditions that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study.

Primary outcomes:
measure: Psoriasis Area and Severity Index (PASI).
timeFrame: After four weeks of treatment.
Secondary outcomes:
measure: Dermatology Life Quality Index (DLQI).
timeFrame: After four weeks of treatment.
Other outcomes:
Locations:
city: Ramat Gan
country: Israel
facility: Phototherapy and Dermatology Day Care Center, Sheba Medical Center, Tel Hashomer
Study officials:
References:
Clinical trial NCT01926652: Safety and Pharmacokinetics Study of Amlodipine 10mg and Candesartan 32mg
Official title: An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Amlodipine 10mg and Candesartan 32mg in Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Shin Poong Pharmaceutical Co. Ltd.
Sponsor class: INDUSTRY
First posted: 2013-08-21
Enrollment: 34
Sex: MALE
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Clinical trial to evaluate the pharmacokinetic interactions and safety between single dose of amlodipine 10mg and candesartan 32mg and the combination dose amlodipine 10mg with candesartan 32mg in healthy male volunteers.


Eligibility criteria: Inclusion Criteria:

1. Male volunteers in the age between 20 and 55 years old(inclusive).
2. Body weight \>= 55kg and Body mass index (BMI) in the range of calculated IBW ±20%.
3. Subjects without a hereditary problems or chronic desease.
4. Subjects whose clinical laboratory test values are inside the accepted normal range.
5. Understand the requirements of the study and voluntarily consent to participate in the study.

Exclusion Criteria:

1. Subjects with a history of gastrointestinal diseases which might significantly change ADME of medicines.
2. Systolic blood pressure range ≥150 mmHg or ≤ 100 mmHg or diastolic blood pressure range ≥ 95 mmHg or ≤ 60 mmHg.
3. Subject with symptoms of acute disease within 14days prior to study medication dosing.
4. Subjects with a history of clinically significant allergies of amlodipin or candesartan or CCB or other medicine (ex. aspirin or antibiotics).
5. Subjects with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
6. Serum creatinine \> 1.2mg/dL.
7. smoking \> 10 cigarettes/day.
8. alcohol \> 210g/week.
9. Positive test results for drug test in urin or subject with history of substance abuse.
10. Participation in any clinical investigation within 2 months prior to study medication dosing.
11. Subjects with whole blood donation within 2 months, component blood donation within 1 month and blood transfusion within 1 month prior to study medication dosing.
12. Subjects considered as unsuitable based on medical judgement by investigators.

Primary outcomes:
measure: AUC, Cmax
timeFrame: 7days, 10days
Secondary outcomes:
measure: Cmin, tmax, CL/F
timeFrame: 7days, 10days
Other outcomes:
Locations:
city: Daejeon
country: Korea, Republic of
facility: Chungnam national university hospital, clinical trial center
state: Chungcheongbul-do
Study officials:
References:
Clinical trial NCT03369652: Telephone Contact Between Hospital and General Practitioner About Medication Review for Older Patients
Official title: Can Telephone Contact After Discharge Between Geriatrician, Clinical Pharmacist and General Practitioner About Medication Review in Hospital Improve the Medication in Older Patients? A Feasibility Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Older Patients
Medication Review
Cross-sectional Communication
Lead sponsor: Odense University Hospital
Sponsor class: OTHER
First posted: 2017-12-12
Enrollment: 232
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: In this trial, the feasibility of cooperation between clinical pharmacists and physicians by conducting a telephone follow-up conversation between the hospital geriatrician, the general practitioner and the clinical pharmacist is evaluated. During hospital stay the clinical pharmacist and the geriatrician will review older patients' medication and discuss the future treatment with the general practitioner after discharge by telephone or medico-technology.

The first part of the feasibility study will be a qualitative baseline measure of characteristics of the participants and work flow. The second part will be a pilot randomized controlled study where participants will be allocated to either usual care or medication review and follow up contact


Eligibility criteria: Inclusion Criteria:

\* 5 drugs or more

Exclusion Criteria:

* Terminal illness
* Not able to speak and understand Danish

Primary outcomes:
measure: Changes in number of medications
timeFrame: At admission and at discharge
measure: Parts of the intervention completed
timeFrame: Day 1 after discharge
measure: Changes in the Electronic Medication Profile (FMK)
timeFrame: 14 days after discharge
Secondary outcomes:
measure: Number of readmissions
timeFrame: within 30 days after discharge
measure: Number of emergency visits
timeFrame: within 30 days after discharge
measure: Number of visits at general practitioner
timeFrame: within 30 days after discharge
measure: Patient satisfaction with the discharge
timeFrame: 14 days after discharge
measure: Changes in patient-experienced quality of life
timeFrame: At admission and 14 days after discharge
measure: Health care professionals satisfaction
timeFrame: 3 months after implementation
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: Odense University Hospital
city: Svendborg
country: Denmark
facility: Svendborg Sygehus
Study officials:
affiliation: University of Southern Denmark
name: Anton Pottegård, phd
role: STUDY_CHAIR
References:
Clinical trial NCT00052052: An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Official title: An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Lung Disease
Pulmonary Fibrosis
Keywords: idiopathic pulmonary fibrosis
IPF
Lead sponsor: InterMune
Sponsor class: INDUSTRY
First posted: 2003-01-23
Enrollment: 210
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Study GIPF-004 is an open-label, multicenter study that will enroll approximately 250 patients who complete Protocol GIPF-001. The purpose of this study is to assess the safety and efficacy of continued IFN-gamma 1b therapy in this well-defined cohort of patients for up to 48 weeks.


Eligibility criteria: Male or Female

Idiopathic Pulmonary Fibrosis

20-79 years

Must have participated in the InterMune protocol GIPF-001 study.

Primary outcomes:
measure: FVC, dyspnea, DLCO, A-a gradient at rest,SGRQ,survival time, use of supplemental oxygen, QOL SF-36, TLC, time to lung transplantation or death due to IPF
timeFrame: 48 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: University of Washington Medical Center
state: Washington
Study officials:
affiliation: InterMune
name: Javier Szwarcberg, MD
role: STUDY_DIRECTOR
References: